These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16003667)

  • 41. Patient and facility characteristics associated with benzodiazepine prescribing for veterans with PTSD.
    Lund BC; Bernardy NC; Vaughan-Sarrazin M; Alexander B; Friedman MJ
    Psychiatr Serv; 2013 Feb; 64(2):149-55. PubMed ID: 23154834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study.
    Zifko UA; Rupp M; Schwarz S; Zipko HT; Maida EM
    J Neurol; 2002 Aug; 249(8):983-7. PubMed ID: 12195441
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improving care for rural veterans: are high dual users different?
    Nayar P; Yu F; Apenteng B
    J Rural Health; 2014; 30(2):139-45. PubMed ID: 24689539
    [TBL] [Abstract][Full Text] [Related]  

  • 44. P300 and treatment effect of modafinil on fatigue in multiple sclerosis.
    Nagels G; D'hooghe MB; Vleugels L; Kos D; Despontin M; De Deyn PP
    J Clin Neurosci; 2007 Jan; 14(1):33-40. PubMed ID: 17138067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological treatments for fatigue associated with palliative care.
    Peuckmann V; Elsner F; Krumm N; Trottenberg P; Radbruch L
    Cochrane Database Syst Rev; 2010 Nov; (11):CD006788. PubMed ID: 21069692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis.
    Sevim S; Kaleağası H; Taşdelen B
    Mult Scler Relat Disord; 2017 Aug; 16():40-43. PubMed ID: 28755683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fatigue and psychiatric illness in a large community sample of persons with multiple sclerosis.
    Chwastiak LA; Gibbons LE; Ehde DM; Sullivan M; Bowen JD; Bombardier CH; Kraft GH
    J Psychosom Res; 2005 Nov; 59(5):291-8. PubMed ID: 16253619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients.
    Putzki N; Katsarava Z; Vago S; Diener HC; Limmroth V
    Eur Neurol; 2008; 59(3-4):136-42. PubMed ID: 18057900
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors.
    Hirsh AT; Turner AP; Ehde DM; Haselkorn JK
    Arch Phys Med Rehabil; 2009 Apr; 90(4):646-51. PubMed ID: 19345781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Access to multiple sclerosis specialty care.
    Turner AP; Chapko MK; Yanez D; Leipertz SL; Sloan AP; Whitham RH; Haselkorn JK
    PM R; 2013 Dec; 5(12):1044-50. PubMed ID: 23920332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Provision of potentially teratogenic medications to female veterans of childbearing age.
    Schwarz EB; Longo LS; Zhao X; Stone RA; Cunningham F; Good CB
    Med Care; 2010 Sep; 48(9):834-42. PubMed ID: 20706159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polypharmacy in multiple sclerosis: relationship with fatigue, perceived cognition, and objective cognitive performance.
    Thelen JM; Lynch SG; Bruce AS; Hancock LM; Bruce JM
    J Psychosom Res; 2014 May; 76(5):400-4. PubMed ID: 24745782
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model.
    Turner AP; Kivlahan DR; Sloan AP; Haselkorn JK
    Mult Scler; 2007 Nov; 13(9):1146-52. PubMed ID: 17967842
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients.
    Brioschi A; Gramigna S; Werth E; Staub F; Ruffieux C; Bassetti C; Schluep M; Annoni JM
    Eur Neurol; 2009; 62(4):243-9. PubMed ID: 19672078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of Fatigue Impact in Persons With Long-Standing Multiple Sclerosis.
    Morrison JD; Stuifbergen AK
    J Neurosci Nurs; 2016 Jun; 48(3):143-50. PubMed ID: 27136408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
    da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
    BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Applying Lean Six Sigma to improve medication management.
    Nayar P; Ojha D; Fetrick A; Nguyen AT
    Int J Health Care Qual Assur; 2016; 29(1):16-23. PubMed ID: 26771058
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Psychosocial correlates of fatigue in multiple sclerosis.
    Schwartz CE; Coulthard-Morris L; Zeng Q
    Arch Phys Med Rehabil; 1996 Feb; 77(2):165-70. PubMed ID: 8607741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health care coverage and access to care: the status of Minnesota's veterans.
    Jonk YC; Call KT; Cutting AH; O'Connor H; Bansiya V; Harrison K
    Med Care; 2005 Aug; 43(8):769-74. PubMed ID: 16034290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.
    Geisler MW; Sliwinski M; Coyle PK; Masur DM; Doscher C; Krupp LB
    Arch Neurol; 1996 Feb; 53(2):185-8. PubMed ID: 8639070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.